目的:探讨血糖变异系数(CV)与非增殖期糖尿病视网膜病变(NPDR)患者黄斑区微血管改变及视功能的关系,为优化血糖管理策略、延缓糖尿病视网膜病变(DR)进展提供新的视角。
方法:横断面研究。 收集2025年1月至2026年3月本院收治的NPDR患者为研究对象。根据NPDR严重程度分为轻度组、中度组、重度组,再根据视功能是否正常分为视功能正常组和视功能异常组。多元线性回归分析CV与黄斑区微血管参数的相关性,受试者工作特征(ROC)曲线分析CV对NPDR严重程度进展的评估价值,多因素Logistic回归分析影响视功能的因素,采用广义线性模型探究CV对NPDR严重程度和视功能的交互作用,限制性立方样条模型(RCS)分析CV在不同严重程度下与视功能的剂量反应关系。
结果: 本研究共纳入NPDR患者160例160眼(每例患者仅纳入1眼,若双眼均符合NPDR诊断,则采用随机数字表法随机选择1眼)。根据NPDR严重程度分为轻度组62例62眼(男33例,女29例,平均年龄58.26±6.53岁)、中度组58例58眼(男30例,女28例,平均年龄59.14±6.64岁)、重度组40例40眼(男21例,女19例,平均年龄60.33±6.71岁)。三组患者的病程、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、CV、黄斑中心凹无血管区(FAZ)面积、浅层毛细血管丛(SCP)、上方SCP、下方SCP、深层毛细血管丛(DCP)、上方DCP、下方DCP均有差异(均P<0.001)。多元线性回归分析显示,CV水平与FAZ面积呈正相关(β>0),与平均SCP、上方SCP、下方SCP、平均DCP、上方DCP、下方DCP呈负相关(β<0)(均P<0.001)。ROC分析显示,CV在评估NPDR进展为中度及重度时,AUC=0.851,灵敏度=0.828,特异度=0.810,最佳截断值为29.82%; 在评估NPDR进展为重度时,AUC=0.896,灵敏度=0.900,特异度=0.838,最佳截断值为36.21%。根据视功能分为视功能正常组88例88眼(男46例,女42例,平均年龄58.51±6.81岁),视功能异常组72例72眼(男38例,女34例,平均年龄59.82±6.93岁)。视功能异常组的病程、FBG、HbA1c、CV、FAZ面积高于视功能正常组,平均SCP、上方SCP、下方SCP、平均DCP、上方DCP、下方DCP低于视功能正常组(均P<0.001)。视功能异常预测模型1包含因素:病程、FBG、HbA1c、FAZ面积、平均SCP、平均DCP; 预测模型2包含因素:FBG、HbA1c、FAZ面积、平均SCP、平均DCP、CV。与模型1比较,模型2的AUC(0.817,95%CI:0.785-0.849)、IDI(0.082,95%CI:0.064-0.096)、NRI(0.618,95%CI:0.479-0.819)均明显提高(均P<0.05),且Hosmer-Lemeshow检验显示两模型的拟合优度良好。交互作用显示,随着CV水平的升高,患者NPDR严重程度和视功能异常的正关联关系逐渐增强。RCS显示,CV水平在不同严重程度下与视功能异常存在非线性剂量-反应关系(非线性检验, χ2=16.124,P<0.001)。
结论:CV是NPDR患者黄斑区微血管损伤和视功能异常危险因素。随着CV升高,FAZ面积扩大、SCP及DCP血管密度降低,NPDR严重程度及视功能损害风险逐级增加。在NPDR患者的血糖管理过程中,除关注HbA1c达标外,还应重视血糖波动的控制,建议将CV控制在29.82%以下以降低NPDR进展风险,将CV≥36.21%作为重度NPDR及视功能损害的高危预警阈值,将CV作为评估DR风险和指导治疗决策的补充指标。
AIM: To investigate the relationship between the coefficient of variation(CV)of blood glucose and microvascular changes in the macular area and visual function in patients with non-proliferative diabetic retinopathy(NPDR), and to provide a new perspective for optimizing blood glucose management strategies and delaying the progression of diabetic retinopathy(DR).
METHODS:This was a cross-sectional study. Patients with NPDR admitted to our hospital from January 2025 to March 2026 were enrolled and divided into mild NPDR group, moderate NPDR group, and severe NPDR group according to NPDR severity, and further divided into normal visual function group and abnormal visual function group based on visual function status. Multiple linear regression was used to analyze the correlation between CV and macular microvascular parameters. Receiver operating characteristic(ROC)curves were constructed to evaluate the value of CV in assessing the progression of NPDR severity. Multivariate logistic regression was performed to identify independent influencing factors of visual function. Generalized linear models were employed to explore the interaction between CV and NPDR severity and visual function. Restricted cubic spline(RCS)models were used to analyze the dose-response relationship between CV and visual function across different severity levels.
RESULTS:A total of 160 patients(160 eyes)with non-proliferative diabetic retinopathy(NPDR)were enrolled in this study. Only one eye per patient was included as the study eye. If both eyes met the diagnostic criteria for NPDR, one eye was randomly selected using a random number table. According to the severity of NPDR, the patients were divided into a mild group(62 patients, 62 eyes), a moderate group(58 patients, 58 eyes), and a severe group(40 patients, 40 eyes). The mild group included 33 male and 29 female patients, with a mean age of 58.26±6.53 y; the moderate group included 30 male and 28 female patients, with a mean age of 59.14±6.64 y; and the severe group included 21 male and 19 female patients, with a mean age of 60.33±6.71 y. Statistically significant differences were observed among the three NPDR severity groups in disease duration, fasting blood glucose(FBG), glycated hemoglobin(HbA1c), CV, foveal avascular zone(FAZ)area, mean superficial capillary plexus(SCP), upper SCP, lower SCP, mean deep capillary plexus(DCP), upper DCP, and lower DCP(all P<0.05). Multiple linear regression analysis demonstrated that CV was positively correlated with FAZ area(β>0)and negatively correlated with mean SCP, upper SCP, lower SCP, mean DCP, upper DCP, and lower DCP(β<0, all P<0.05). ROC analysis revealed that when CV assessed NPDR progression to moderate and severe stages, the area under the curve(AUC)was 0.851, with a sensitivity of 0.828, a specificity of 0.810, and an optimal cut-off value of 29.82%; when assessing progression to severe NPDR, the AUC was 0.896, with a sensitivity of 0.900, a specificity of 0.838, and an optimal cut-off value of 36.21%. According to visual function status, the patients were divided into a normal visual function group(88 patients, 88 eyes)and an abnormal visual function group(72 patients, 72 eyes). The normal visual function group included 46 male and 42 female patients, with a mean age of 58.51±6.81 y; the abnormal visual function group included 38 male and 34 female patients, with a mean age of 59.82±6.93 y. The abnormal visual function group had significantly longer disease duration and higher FBG, HbA1c, CV, and FAZ area than the normal visual function group, while mean SCP, upper SCP, lower SCP, mean DCP, upper DCP, and lower DCP were significantly lower(all P<0.05). Predictive model 1 for abnormal visual function included disease duration, FBG, HbA1c, FAZ, mean SCP, and mean DCP; predictive model 2 included FBG, HbA1c, FAZ, mean SCP, mean DCP, and CV. Compared with model 1, model 2 showed significantly improved AUC(0.817, 95%CI: 0.785-0.849), integrated discrimination improvement(IDI; 0.082, 95%CI: 0.064-0.096), and net reclassification improvement(NRI; 0.618, 95%CI: 0.479-0.819)(all P<0.05), and the Hosmer-Lemeshow test indicated good calibration for both models. Interaction analysis showed that the positive association between NPDR severity and abnormal visual function gradually strengthened with increasing CV levels. RCS analysis revealed a non-linear dose-response relationship between CV level and abnormal visual function across different severity levels(nonlinear test, χ2=16.124, P<0.001).
CONCLUSION: CV is a risk factor for macular microvascular injury and visual function abnormalities in patients with NPDR. As CV increases, FAZ area expands, SCP and DCP vessel density decreases, and the risk of NPDR progression and visual function impairment increases stepwise. In the glycemic management of NPDR patients, in addition to achieving HbA1c targets, attention should be paid to the control of blood glucose fluctuations. It is recommended to maintain CV below 29.82% to reduce the risk of NPDR progression, and to use CV≥36.21% as a high-risk warning threshold for severe NPDR and visual function impairment. CV should be considered as a supplementary indicator for assessing DR risk and guiding treatment decisions.
2024年度张家港市科技计划项目(医疗卫生科技创新指导项目)(No.ZKYL2440); 江苏医药职业学院2024年度校地协同创新研究项目(No.202490620)